Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:2542-5684
-
Container-title:Liver Research
-
language:en
-
Short-container-title:Liver Research
Author:
Saeed AnzelORCID,
Rai Kuldeep DalpatORCID,
Saeed Muzammil
Reference9 articles.
1. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis;Diehl;N Engl J Med.,2017
2. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease;Angulo;Gastroenterology,2015
3. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis;Dulai;Hepatology,2017
4. Pharmacotherapy for NASH: current and emerging;Konerman;J Hepatol,2018
5. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018